Micropulse Transscleral Cyclophotocoagulation In The Treatment Of Glaucoma - A 1-Year Retrospective Observational Study
Published 2025 - 43rd Congress of the ESCRS
Reference: PP24.14 | Type: Poster | DOI: 10.82333/gh22-sa55
Authors: Paulina Langosz* 1 , Krzysztof Eder 2 , Martyna Nocoń-Bratek 1 , Wojciech Maruszczyk 1 , Katarzyna Gontarz 1 , Michał Bogocz 2 , Dorota Wyględowska-Promieńska 2 , Adrian Smędowski 3
1Department of Ophthalmology,Prof Gibinski University Clinical Center,Katowice,Poland, 2Department of Ophthalmology,Prof Gibinski University Clinical Center,Katowice,Poland;Department of Ophthalmology,Medical University of Silesia,Katowice,Poland, 3Department of Ophthalmology,Prof Gibinski University Clinical Center,Katowice,Poland;Department of Ophthalmology,Medical University of Silesia,Katowice,Poland;Ophthalmology,GlaucoTech sp. z o.o.,Katowice,Poland
Purpose
The purpose of our work was to evaluate the efficacy and complications of micropulse transscleral cyclophotocoagulation (MP-TSCPC) as a treatment modality for various types of glaucoma.
Setting
371 eyes underwent 382 MP-TSCPC procedures over three years as a treatment for diverse types of glaucoma. The mean age of the population was 69 with the average of 3 IOP lowering medications beforehand. Of the procedures, 199 were performed on pseudophakic eyes, 179 on phakic and 4 on aphakic eyes. Prior laser glaucoma procedures included LPI for 80 of the eyes and SLT for 58 eyes.In 330 eyes the procedure was performed for the first time and in 52 eyes there has been prior MP-TSCPC procedure.
Methods
In this retrospective observational study the abovementioned group of eyes has been observed for 12±3 months especially in terms of BCVA and IOP profile. The latter have been measured and analyzed by means of the Goldmann applanation tonometry and corrected for CCT. Further, surgical complications, need for further topical and systemic glaucoma pharmacotherapy as well as the necessity of repeated surgical interventions during the observation period have been analyzed. Subjective ailments reported by the patients in the period of observation have been numbered.
Results
We have observed an IOP drop from 21.0 on admission to 17 on discharge, with further values of 17.0; 16.0; 16.0; 16.0; 15.0; 16.0 at the 2-weeks, 1, 3, 6, 9 and 12-month respectively. In 12-month period we have not observed any significant reduction in the number of topical IOP-lowering drugs, with the median of 3. We have observed a decrease in the need for systemic treatment. On admission systemic treatment was used in 35 patients. At 2-weeks, 1, 3, 6 and 9-month control points 25, 25, 21, 16 and 10 patients respectively needed systemic treatment. At 12-month control only 8 patients required systemic treatment.The only relevant complication was recurrence of elevated IOP. Other complications such as conjunctival injection were transient
Conclusions
Micropulse transscleral cyclophotocoagulation has been proven to be an effective anti-glaucoma treatment modality, decreasing intraocular pressure and the need for follow-up surgical procedures. Despite statistically significant IOP decrease after MP-TSCPC, in the majority of cases topical IOP-lowering therapy must be continued. Significant decrease of systemic treatment necessity contributes to the improvement of the quality of life and decreases the risk of negative drug interactions and medications’ side effects. The subjective ailments reported by patients have been found to be at an acceptable level as the majority of the population observed has reported a considerable improvement in the quality of life.